B
Bull
Bull · 25%CC
$11.05
Scenario price
$12.620
-0.119 (-0.94%)At close
Loading chart…
- High
- 12.890
- Open
- 12.800
- VWAP
- 12.69
- Volume
- 2.14M
- Mkt Cap
- 3.44B
- Low
- 12.550
- Amount
- 27.21M
- EV/EBITDA, TTM
- 8.28
The Chemours Company is engaged in providing industrial and specialty chemical products for markets, including coatings, plastics, refrigeration and air conditioning, transportation, semiconductors, electronics, general industrial, and oil and gas. The Company operates through three segments, which include Thermal & Specialized Solutions, Titanium Technologies, and Advanced Performance Materials. The Thermal & Specialized Solutions segment is a provider of refrigerants, thermal management solutions, propellants, blowing agents, and specialty solvents. The Titanium Technologies segment is a provider of titanium dioxide (Tio2), a white pigment used to deliver whiteness, brightness, opacity, durability, efficiency, and protection across a variety of applications. The Advanced Performance Materials segment is a provider of polymers and materials that deliver attributes including low friction coefficients, extreme temperature resistance, weather resistance, and others.
AI analysis of The Chemours Company (CC)
SellChemours Co is not a good buy right now. The current price is $12.74, significantly below the analyst price target of $16, indicating potential upside. However, the stock has a very low RSI of 18.287, suggesting it is oversold but may not recover soon due to ongoing challenges. The company is facing serious risks, including a recent 18.7% drop in share price after disappointing earnings and multiple class action lawsuits, which could further impact investor confidence.
Analyst Ratings (8)
+27.89% upside
Buy
7 Buy
1 Hold
0 Sell
Current: 12.62
Low
13.00
Average
16.14
High
19.00
Barclays
Hold
$16
2026-10-12
Barclays
2026-10-12
Price Target
$16
Hold
UBS
Neutral
$16
2026-10-05
UBS
2026-10-05
Price Target
$16
Neutral
Mizuho
Outperform
$18
2026-09-30
Mizuho
2026-09-30
Price Target
$18
Outperform
JPMorgan
Neutral
$15
2026-08-13
JPMorgan
2026-08-13
Price Target
$15
Neutral
BMO Capital
Buy
$18
2026-08-13
BMO Capital
2026-08-13
Price Target
$18
Buy
Valuation Metrics
The current forward P/E ratio for The Chemours Company (CC) is 7.31, compared to its 5-year average forward P/E of 9.70.
Alphio AI Price Scenarios for CC
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Whales holding CC
Events Timeline
News
7.010-20PRnewswireChemours Company Faces Securities Class Action Lawsuit
7.010-20PRnewswireChemours Securities Class Action Lawsuit Filed
7.010-20PRnewswireChemours Sued for Securities Fraud After 18.63% Stock Plunge
7.010-20PRnewswireChemours Faces Class Action Lawsuit Over Misleading Statements
7.010-19PRnewswireChemours Takes Action to Protect Refrigerant Technology IP
CC FAQ — answered by Alphio AI
The Chemours Company is engaged in providing industrial and specialty chemical products for markets, including coatings, plastics, refrigeration and air conditioning, transportation, semiconductors, electronics, general industrial, and oil and gas. The Company operates through three segments, which include Thermal & Specialized Solutions, Titanium Technologies, and Advanced Performance Materials. The Thermal & Specialized Solutions segment is a provider of refrigerants, thermal management solutions, propellants, blowing agents, and specialty solvents. The Titanium Technologies segment is a provider of titanium dioxide (Tio2), a white pigment used to deliver whiteness, brightness, opacity, durability, efficiency, and protection across a variety of applications. The Advanced Performance Materials segment is a provider of polymers and materials that deliver attributes including low friction coefficients, extreme temperature resistance, weather resistance, and others. It operates in the Basic Materials sector (CHEMICALS & ALLIED PRODUCTS industry).
Chemours Co is not a good buy right now. The current price is $12.74, significantly below the analyst price target of $16, indicating potential upside. However, the stock has a very low RSI of 18.287, suggesting it is oversold but may not recover soon due to ongoing challenges. The company is facing serious risks, including a recent 18.7% drop in share price after disappointing earnings and multiple class action lawsuits, which could further impact investor confidence.
8 analysts cover CC: 7 rate it Buy, 1 Hold and 0 Sell. The average price target is 16.14.
Community
More ↗
Once the Buy Setup of $CC forms on the 1-hour time frame, this coin will be unstoppable in its rise.
Show more
$GENIUS $CC $SUN I used to think copy trading was just another trend that sounded better than it actually was, so I kept ignoring it. Looking back, that was probably one of my biggest mistakes. I eventually decided to give Alyssa Tan's market insights a chance and started with $3,750. I didn't expect much, I just wanted a more disciplined approach to trading. Three months later, I've already accumulated over $96,800 in profits, and I've learned far more about risk management and market timing than I ever did trying to figure everything out on my own. I'm genuinely grateful to everyone who kept recommending Alyssa Tan. If I hadn't finally reached out, I don't think I would have realized how valuable her guidance truly is. Taking that step turned out to be one of the best decisions I've made in my trading journey.
Show more
$ILY $CC $preSPCX A few days ago, while scrolling through Bitget, I came across a post about Alyssa Tan, a crypto trader who caught my attention. I visited her page and was impressed by the number of positive testimonials from different people who tagged her. I was convinced and decided to invest $15,000 in her services. I am thrilled to share with you all that this investment has already yielded returns of $140,000. I will always recommend Alyssa Tan to anyone looking to grow their finances. I will also share proof of my profits and some testimonials I saw on her page.
Show moreThis page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.